surufatinib
Small moleculeexperimental
Clinical trial activity
86 trials · 36 clinical orgs · 0 marketing orgs
Phase 1
22
Phase 2
68
Phase 3
3
Phase 4
1
Earliest trial started Jul 31, 2011 (NCT01465880)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Angiogenesis Inhibitors · Phase 2
- Angiogenesis Modulating Agents · Phase 2
- Antineoplastic Agents, Immunological · Phase 2
- Bile Duct Neoplasms · Phase 2
- Biliary Tract Neoplasms · Phase 2/Phase 3
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Neuroendocrine · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Chemoradiotherapy · Phase 2
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Drugs, Investigational · Phase 2
- Drug Therapy · Phase 2
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- Exocrine Pancreatic Insufficiency · Phase 1
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Gallbladder Neoplasms · Phase 2
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Healthy Volunteers · Phase 1
- Immunotherapy · Phase 2
- Intestinal Neoplasms · Phase 2
- Kidney Failure, Chronic · Phase 1
- Liver Diseases · Phase 1
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1/Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neuroendocrine Tumors · Phase 3
- Osteosarcoma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2/Phase 3
- Rhabdomyosarcoma · Phase 1/Phase 2
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Thyroid Carcinoma, Anaplastic · Phase 1/Phase 2
- Thyroid Neoplasms · Phase 2
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
FLT1 inhibitor
KDR inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
FLT4 inhibitor
CSF1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1- Mol. weight
- 480.59 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297190 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07279532 | Phase 2 | Jan 1, 2026 | Zhejiang University |
| NCT07272512 | Phase 4 | Nov 30, 2025 | Fudan University |
| NCT07156019 | Phase 2 | Oct 31, 2025 | Chinese Academy of Medical Sciences |
| NCT07086469 | Phase 2 | Jul 20, 2025 | Sun Yat-Sen University |
| NCT07086456 | Phase 2 | Jul 20, 2025 | Sun Yat-Sen University |
| NCT06654947 | Phase 2 | Jan 31, 2025 | Fujian Medical University |
| NCT06876844 | Phase 2 | Dec 30, 2024 | Jiao Tong University |
| NCT06719700 | Phase 2 | Nov 30, 2024 | Sun Yat-Sen University |
| NCT06656559 | Phase 2 | Oct 31, 2024 | Tianjin Medical University |
| NCT06708858 | Phase 2 | Aug 15, 2024 | People's Liberation Army of China |
| NCT06531291 | Phase 2 | Aug 10, 2024 | Jiao Tong University |
| NCT06447636 | Phase 2 | Aug 1, 2024 | Fudan University |
| NCT06361030 | Phase 2 | Jun 1, 2024 | Huazhong University of Science and Technology |
| NCT06414915 | Phase 2 | Jun 1, 2024 | Government of China, National Cancer Center, China |
| NCT06329947 | Phase 2 | May 22, 2024 | Sun Yat-Sen University |
| NCT06313554 | N/A | May 20, 2024 | Fudan University |
| NCT06361888 | Phase 2/Phase 3 (Phase 3) | May 8, 2024 | University of Washington |
| NCT06255262 | Phase 1/Phase 2 (Phase 2) | Feb 15, 2024 | China Medical University |
| NCT06199882 | Phase 2 | Feb 1, 2024 | Chinese Academy of Medical Sciences |
| NCT06156332 | N/A | Jan 28, 2024 | Second Military Medical University |
Showing 20 of 86 trials
Page 1 / 5
Organizations
Research & Development (36)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hutchison MediPharma | For profit | 14 | 14 | 4 | 2018 |
| Sun Yat-Sen University | Academic/Hospital | 13 | 13 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 9 | 5 | 2 | 2019 |
| Fudan University | Academic/Hospital | 9 | 9 | 3 | 2020 |
| Huazhong University of Science and Technology | Academic/Hospital | 7 | 6 | 1 | 2022 |
| Fujian Medical University | Academic/Hospital | 6 | 6 | 1 | 2021 |
| Jiao Tong University | Academic/Hospital | 4 | 4 | 2 | 2021 |
| Peking University | Academic/Hospital | 3 | 3 | 2 | 2018 |
| People's Liberation Army of China | Government | 3 | 2 | 1 | 2021 |
| Tianjin Medical University | Academic/Hospital | 3 | 3 | 1 | 2022 |
| BeOne Medicines | For profit | 2 | 0 | 1 | 2021 |
| Nanjing University | Academic/Hospital | 2 | 2 | 1 | 2022 |
| University of Washington | Academic/Hospital | 2 | 1 | 2 | 2022 |
| Wuhan University | Academic/Hospital | 2 | 1 | 1 | 2022 |
| Zhejiang University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Anhui Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Changhai Hospital | Academic/Hospital | 1 | 1 | 1 | 2023 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
36 organizations
Page 1 / 2